ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

JNJ Johnson and Johnson

158.26
0.30 (0.19%)
29 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Johnson and Johnson NYSE:JNJ NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.30 0.19% 158.26 159.14 158.11 158.11 6,293,906 00:00:00

AC Immune Sees Positive Data in Trial for Alzheimer's Disease Treatment

12/11/2021 2:44pm

Dow Jones News


Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Johnson and Johnson Charts.

By Chris Wack

 

AC Immune SA said it saw positive new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc.

The company said ACI-35.030 is the first Alzheimer's disease vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.

AC Immune said results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030.

Interim safety data further support ACI-35.030's favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.

As previously reported, the ongoing Phase 1b/2a study has been expanded to include a total of 24 Alzheimer's disease participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.

AC Immune shares were up 11% to $6.70 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

November 12, 2021 09:29 ET (14:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Johnson and Johnson Chart

1 Year Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

Your Recent History

Delayed Upgrade Clock